Items Tagged ‘sunitinib’

December 5th, 2016

Cabometyx™ Improves Time to Cancer Progression as Initial Therapy in Kidney Cancer

By

The agent Cabometyx™ (cabozantinib) improves anti-cancer responses and time to cancer progression compared to Sutent® (sunitinib) when used as initial therapy for advanced kidney cancer. These results were recently published in the Journal of Clinical Oncology. The kidneys are a pair of organs with multiple functions. Renal cell carcinoma is the most common type of […]

View full entry

Tags: AXL, Cabometyx, cabozantinib, General Renal Cancer, kidney cancer, MET, metastatic, mRCC, News, Renal Cancer, sunitinib, Sutent


May 19th, 2015

Target Therapy Sutent® Promising in Advanced Thyroid Cancer

By

The targeted therapy Sutent® (sunitinib) appears effective in the treatment of patients with advanced differentiated thyroid cancers. The Endocrine Society announced these Phase II trial findings in a press release. Study results were also presented at the Endocrine Society’s 97th annual meeting in San Diego, March 5–8, 2015. Differentiated thyroid cancer is the most common […]

View full entry

Tags: News, sunitinib, Sutent, targeted therapy, Thyroid Cancer


March 17th, 2015

Sutent® Maintenance Therapy Found Active in Small Cell Lung Cancer

By

Doctors have reported that maintenance therapy using Sutent® (sunitinib) delays the time to cancer progression and improves survival in patients with extensive-stage small-cell lung cancer (SCLC).  These encouraging results were recently reported in the online March 3, 2015 Journal of Clinical Oncology. Small-cell lung cancer is a fast-growing type of lung cancer and accounts for […]

View full entry

Tags: extensive-stage, Lung Cancer, maintenance therapy, News, sclc, small cell lung cancer, sunitinib, Sutent